cached image

David M. Holtzman

Affiliations: 
Neurology Washington University, Saint Louis, St. Louis, MO 
Area:
Alzheimer's, amyloid
Website:
http://neuro.wustl.edu/aboutus/facultybiographies/holtzman.htm
Google:
"David Holtzman"
Bio:

David Holtzman is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, and a member of the Hope Center for Neurological Disorders. A major interest in his lab is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS particularly as these mechanisms may relate to Alzheimer's disease (AD) and injury to the developing brain.

Mean distance: 14.48 (cluster 31)
 
Cross-listing: Alzheimer's Tree

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Cadiz MP, Gibson KA, Todd KT, et al. (2024) Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. The Journal of Experimental Medicine. 221
Vance JM, Farrer LA, Huang Y, et al. (2024) Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease. Annals of Neurology
Seo DO, Holtzman DM. (2024) Current understanding of the Alzheimer's disease-associated microbiome and therapeutic strategies. Experimental & Molecular Medicine
Chen Y, Song S, Parhizkar S, et al. (2023) APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell
Litvinchuk A, Suh JH, Guo JL, et al. (2023) Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron
Tabor GT, Holtzman DM. (2023) Current status of amyloid-targeting immunotherapies for Alzheimer's disease. Science Translational Medicine. 15: eadk9993
Yin Z, Rosenzweig N, Kleemann KL, et al. (2023) APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints. Nature Immunology
Lau SF, Wu W, Wong HY, et al. (2023) The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer's disease pathology. Nature Aging
Self WK, Holtzman DM. (2023) Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine. 29: 2187-2199
Jackson RJ, Keiser MS, Meltzer JC, et al. (2023) APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Biorxiv : the Preprint Server For Biology
See more...